Yamauchi PS - Search Results

1

OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.

Kimball AB, Rothman KJ, Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand JM. Kimball AB, et al. Among authors: yamauchi ps. J Am Acad Dermatol. 2015 Jan;72(1):115-22. doi: 10.1016/j.jaad.2014.08.050. Epub 2014 Sep 26. J Am Acad Dermatol. 2015. PMID: 25264239 Free PMC article.

2

Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy.

Iyer S, Yamauchi P, Lowe NJ. Iyer S, et al. Br J Dermatol. 2002 Jan;146(1):118-21. doi: 10.1046/j.0007-0963.2001.04529.x. Br J Dermatol. 2002. PMID: 11841377

3

Idiopathic CD4+T-cell lymphocytopenia associated with vitiligo.

Yamauchi PS, Nguyen NQ, Grimes PE. Yamauchi PS, et al. J Am Acad Dermatol. 2002 May;46(5):779-82. doi: 10.1067/mjd.2002.119672. J Am Acad Dermatol. 2002. PMID: 12004324

4

Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial.

Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, Yamauchi PS. Pariser DM, et al. Among authors: yamauchi ps. J Am Acad Dermatol. 2003 Feb;48(2):227-32. doi: 10.1067/mjd.2003.49. J Am Acad Dermatol. 2003. PMID: 12582393 Clinical Trial.

5

Current systemic therapies for psoriasis: where are we now?

Yamauchi PS, Rizk D, Kormeili T, Patnaik R, Lowe NJ. Yamauchi PS, et al. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S66-77. doi: 10.1016/mjd.2003.550. J Am Acad Dermatol. 2003. PMID: 12894129 Review.

6

Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept.

Yamauchi PS, Lowe NJ, Gindi V. Yamauchi PS, et al. J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S121-2. doi: 10.1016/j.jaad.2005.10.055. J Am Acad Dermatol. 2006. PMID: 16488323 No abstract available.

7

Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.

Yamauchi PS, Lowe NJ. Yamauchi PS, et al. J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S135-8. doi: 10.1016/j.jaad.2005.11.1043. J Am Acad Dermatol. 2006. PMID: 16488328 No abstract available.

8

Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis.

Yamauchi PS, Lowe NJ. Yamauchi PS, et al. Int J Dermatol. 2008 Feb;47(2):202-4. doi: 10.1111/j.1365-4632.2008.03419.x. Int J Dermatol. 2008. PMID: 18211500

9

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. Leonardi CL, et al. Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4. Lancet. 2008. PMID: 18486739 Clinical Trial.

10

Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.

Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F. Strober B, et al. Br J Dermatol. 2008 Aug;159(2):322-30. doi: 10.1111/j.1365-2133.2008.08628.x. Epub 2008 May 22. Br J Dermatol. 2008. PMID: 18503600 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

104 results

Search Page